HCV drugs sofosbuvir, daclatasvir show promise as potential COVID-19 treatment

Using hepatitis C drugs sofosbuvir and daclatasvir in combination with standard care to treat patients with COVID-19 resulted in better 14-day recovery rates and a shorter hospital stay, according to data presented at AIDS 2020.“Laboratory studies have shown that daclatasvir has antiviral activity against SAR-CoV-2 and penetrates well into the lungs where COVID-19 infection can be concentrated, while sofosbuvir has only marginal antiviral activity,” Andrew Hill, MD, PhD, senior visiting research fellow in the pharmacology department at Liverpool University, said during a sessionRead More

Share on facebook
Share on twitter
Share on linkedin